AU1197999A - Treatment and prevention of neurodegenerative diseases using modulators of the interaction of app and a polypeptide defining a pi domain - Google Patents

Treatment and prevention of neurodegenerative diseases using modulators of the interaction of app and a polypeptide defining a pi domain

Info

Publication number
AU1197999A
AU1197999A AU11979/99A AU1197999A AU1197999A AU 1197999 A AU1197999 A AU 1197999A AU 11979/99 A AU11979/99 A AU 11979/99A AU 1197999 A AU1197999 A AU 1197999A AU 1197999 A AU1197999 A AU 1197999A
Authority
AU
Australia
Prior art keywords
modulators
app
prevention
interaction
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11979/99A
Inventor
Joseph Buxbaum
Paul Greengard
Shasta Sabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/957,660 external-priority patent/US5928882A/en
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of AU1197999A publication Critical patent/AU1197999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
AU11979/99A 1997-10-24 1998-10-23 Treatment and prevention of neurodegenerative diseases using modulators of the interaction of app and a polypeptide defining a pi domain Abandoned AU1197999A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08957660 1997-10-24
US08/957,660 US5928882A (en) 1997-10-24 1997-10-24 Treatment and prevention of neurodegenerative diseases using modulators of Fe65
US6208598A 1998-04-17 1998-04-17
US09062085 1998-04-17
PCT/US1998/022523 WO1999021995A1 (en) 1997-10-24 1998-10-23 Treatment and prevention of neurodegenerative diseases using modulators of the interaction of app and a polypeptide defining a pi domain

Publications (1)

Publication Number Publication Date
AU1197999A true AU1197999A (en) 1999-05-17

Family

ID=26741843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11979/99A Abandoned AU1197999A (en) 1997-10-24 1998-10-23 Treatment and prevention of neurodegenerative diseases using modulators of the interaction of app and a polypeptide defining a pi domain

Country Status (2)

Country Link
AU (1) AU1197999A (en)
WO (1) WO1999021995A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007217039A1 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of Alzheimer's disease with inhibitors of APoE binding to APoE receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
US5744313A (en) * 1994-12-09 1998-04-28 The Regents Of The University Of California Assay employing novel protein domain which binds tyrosine phosphorylated proteins
US6218162B1 (en) * 1995-09-27 2001-04-17 Gerald Krystal SH2-containing inositol-phosphatase
FR2740454B1 (en) * 1995-10-26 1997-11-21 Rhone Poulenc Rorer Sa PEPTIDES CAPABLE OF INHIBITING APP ENDOCYTOSIS AND CORRESPONDING NUCLEOTIDE SEQUENCES
AU2316797A (en) * 1996-02-29 1997-09-16 Mount Sinai Hospital Corporation Shc proteins

Also Published As

Publication number Publication date
WO1999021995A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU7470398A (en) Titanium crystal and titanium
AU2276395A (en) Control of photorefractive keratectomy
AU9403798A (en) Human regulatory molecules
AU7250294A (en) Treatment of multidrug resistant diseases
AU3993795A (en) Peptide compounds for prevention and/or treatment of no-mediated diseases
AU1372897A (en) 2-amino-heterocycles and therapeutic uses therefor
AU7592998A (en) Modulators of tissue regeneration
AU2749395A (en) Medical use of bromelain
AU6435398A (en) Prevention and treatment of hepatocellular cancer
AU6160594A (en) Diabetes prevention and treatment
AU1091699A (en) Magnetically compatible peripheral nerve stimulator
AU1556497A (en) Agents for the treatment and prevention of aids
AU1184399A (en) Therapeutic molecules
AU7761694A (en) Intrastromal photorefractive keratectomy
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
AU4347696A (en) Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
AU7484596A (en) Combination therapy for the treatment of diabetes and obesity
AU2438695A (en) Therapeutic phenoxyalkylpyridazines and intermediates therefor
AU2870597A (en) Treatment of liquid
AU1197599A (en) Detection of neurodegenerative diseases
AU1197999A (en) Treatment and prevention of neurodegenerative diseases using modulators of the interaction of app and a polypeptide defining a pi domain
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
AU4546096A (en) Treatment of waste
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AUPN221195A0 (en) Combined waste treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase